

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Single Technology Appraisal

#### Netarsudil for treating open angle glaucoma or ocular hypertension ID1078

#### Provisional Stakeholder List of Consultees and Commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Aerie Pharmaceuticals (netarsudil)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Blind People</li> <li>• Eyecare Trust</li> <li>• Fight for Sight</li> <li>• Henshaws Society for Blind People</li> <li>• International Glaucoma Association</li> <li>• Macular Society</li> <li>• National Federation of the Blind of the UK</li> <li>• OBAC</li> <li>• Royal National Institute of Blind People (RNIB)</li> <li>• SeeAbility</li> <li>• Sense</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Thomas Pocklington Trust</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Independent Optometrists and Dispensing Opticians</li> <li>• Association of Health Professionals in Ophthalmology</li> <li>• Association of Optometrists</li> <li>• British Geriatrics Society</li> <li>• College of Optometrists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Ophthalmologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Council for the Blind</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• A A H pharmaceuticals (acetazolamide, bimatoprost, brinzolamide, brimonidine tartrate, dorzolamide, latanoprost, pilocarpine hydrochloride/nitrate, timolol maleate, travoprost)</li> <li>• Accord (brinzolamide, latanoprost, timolol maleate, travoprost)</li> <li>• Actavis UK (acetazolamide, bimatoprost, dorzolamide, latanoprost)</li> <li>• Advanz Pharma (acetazolamide)</li> <li>• Allergan (bimatoprost, levobunolol hydrochloride)</li> <li>• Alliance Healthcare (acetazolamide, bimatoprost, brinzolamide, brimonidine tartrate, dorzolamide, latanoprost, pilocarpine hydrochloride/nitrate, timolol</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• UK &amp; Eire Glaucoma Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Dudley CCG</li> <li>• NSH Ealing CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• maleate, travoprost)</li> <li>• Aspire Pharma (bimatoprost, brinzolamide, dorzolamide, timolol maleate, travoprost)</li> <li>• Bausch &amp; Lomb UK (pilocarpine hydrochloride/nitrate)</li> <li>• Blumont Pharma (brimonidine tartrate)</li> <li>• Crescent Pharma (acetazolamide)</li> <li>• Dawa (acetazolamide)</li> <li>• DE Pharmaceuticals (acetazolamide, bimatoprost, brinzolamide, brimonidine tartrate, dorzolamide, latanoprost, pilocarpine hydrochloride/nitrate, timolol maleate, travoprost)</li> <li>• FDC International (betaxolol, brimonidine tartrate, dorzolamide, latanoprost, timolol maleate)</li> <li>• Genesis Pharmaceuticals (acetazolamide)</li> <li>• Kent Pharmaceuticals (latanoprost)</li> <li>• Martindale Pharmaceuticals (latanoprost, pilocarpine hydrochloride/nitrate)</li> <li>• Medicom Healthcare (brimonidine tartrate, dorzolamide, latanoprost)</li> <li>• Mylan (bimatoprost, brinzolamide, dorzolamide, timolol maleate, travoprost)</li> <li>• Neon Healthcare (travoprost)</li> <li>• Novartis (apraclonidine, betaxolol, brinzolamide, travoprost)</li> <li>• Pfizer (latanoprost)</li> <li>• Phoenix Healthcare Distribution (acetazolamide, brimonidine tartrate dorzolamide, timolol maleate)</li> <li>• Sandoz (brinzolamide, travoprost)</li> <li>• Santen UK (dorzolamide, tafluprost, timolol maleate)</li> <li>• Sigma Pharmaceuticals (acetazolamide, brimonidine tartrate, dorzolamide, latanoprost, pilocarpine hydrochloride/nitrate)</li> <li>• Teva UK (acetazolamide, travoprost)</li> <li>• Thea Pharmaceuticals (latanoprost, timolol maleate)</li> <li>• Zentiva (brinzolamide, latanoprost, travoprost)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
	<p data-bbox="799 304 1166 338"><u>Relevant research groups</u></p> <ul data-bbox="799 342 1394 645" style="list-style-type: none"> <li>• Cochrane Eyes and Vision Group</li> <li>• Eye Hope</li> <li>• Genomics England</li> <li>• Institute of Ophthalmology, University College London</li> <li>• MRC Clinical Trials Unit</li> <li>• National Eye Research Centre Charity</li> <li>• National Institute for Health Research</li> </ul> <p data-bbox="799 685 1278 719"><u>Associated Public Health Groups</u></p> <ul data-bbox="799 723 1161 792" style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the provisional stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.